GLOBAL GENETIC TESTING MARKET FORECAST 2018-2026

  • You are here:
  • Home
  • Reports
  • GLOBAL GENETIC TESTING MARKET FORECAST 2018-2026

GLOBAL GENETIC TESTING MARKET FORECAST 2018-2026

The Global Genetic testing market is anticipated to grow at a CAGR of 13.56% between 2018 and 2026. Genetic testing includes observing the DNA, a chemical databank that transports directives for the body’s utilities. Genetic testing can reveal changes or alterations in the genes that may cause illness or disease. The Genetic testing market is primarily driven by the following factors:

GLOBAL GENETIC TESTING MARKET FORECAST 2018-2026

Genetic Testing Market by Type (Predisposition Testing, Diagnostic Testing, Newborn Screening, Prenatal Testing) by Application (Cancer Genetic, Prenatal Genetic, Pharmacogenomics, Predisposition) & by Geography.

Request free sample

The Global Genetic testing market is anticipated to grow at a CAGR of 13.56% between 2018 and 2026. Genetic testing includes observing the DNA, a chemical databank that transports directives for the body’s utilities. Genetic testing can reveal changes or alterations in the genes that may cause illness or disease. The Genetic testing market is primarily driven by the following factors:

  • Diagnosing genetic disorders
  • Rise in incidence of genetic diseases
  • Simple, accessible procedure
  • RNA pipeline tests rising
  • Advances in genetic testing for cancer
  • Aging population on the rise

To learn more about this report, request a free sample copy

The important driver increasing growth in the global genetic testing market is the rise in the incidence of genetic diseases and the growing demand for diagnosing genetic disorders. Genetic disorders are the major reasons for chronic diseases. Genetic testing provides technologies that are helpful for the early detection of these genetic disorders and ensures their treatment and prevention. According to the World Health Organization, the global prevalence of all single-gene diseases at birth is approximately 10 per 1,000 births.

 Applications of the Genetic testing market are used extensively for various purposes. In 2015, approx. 15.1 million new cancer cases were registered worldwide, and more than half of these cases are from economically developing countries such as India, China and many more. Prenatal genetic testing is a process which helps detect whether the fetus has any genetic disorders. Majorly, genetic disorders are caused due to mutations in genes or chromosomes of a person. Some of the major genetic disorders are Aneuploidy, trisomy, monosomy, and several other inherited disorders. Pharmacogenomics is a study of congenital differences in human genes that affect a person’s reaction to a particular drug. Pharmacogenomics is a co-integration of pharmaceutical science with genetic sciences. Hence, it is the science of personalizing the drug, which is based on a person’s genetic makeup. A predisposition is an increase in the probability of emergence of a particular disease developed through a person’s genetic makeup. A genetic predisposition outcomes from precise genetic defects that are repeatedly inherited from a parent.

Inaccuracies in results and reimbursement issues are the major factors hindering the Genetic testing market. Genetic testing offers many important opportunities for the assessment of risks in the genes and its diagnosis. But some of the genetic testings do not recognize all of the possible gene mutations caused in particular condition or can just give limited predictive value. Reimbursement decisions about genetic testing are difficult to make due to the lack of general data about the finances involved. The cost of assessing new technologies for genetic testing is also difficult.

The Global Genetic testing market segments include types and applications.

Types are segmented into:

  • PREDICTIVE AND PRESYMPTOMATIC TESTING
  • DIAGNOSTIC TESTING
  • NEWBORN AND PRENATAL TESTING
    • SCREENING METHODS
      • NIPT
      • MSS
    • DIAGNOSTIC TECHNIQUES
      • PCR
      • FISH
      • CGH
    • PREIMPLANTATION GENETIC DIAGNOSIS

Applications are segmented into:

  • Cancer
  • Prenatal
  • Pharmacogenomics
  • Predisposition

This report covers the present market conditions and the growth prospects of the global genetic testings market for 2018-2026 and considered the revenue generated through the sales of genetic testings for types as well as applications to calculate the market size, by considering 2017 as the base year.

Geographically, the global genetic testings market has been segmented on the basis of four major regions, which include:

  • North America – United States & Canada
  • Asia-Pacific – China, India, Japan, Korea & Rest of APAC
  • Europe – United Kingdom, France, Germany, Italy, Spain & Rest of Europe
  • Rest of World- Latin America, Middle East and North Africa & Rest of Africa

The genetic testing market in North America is expected to hold the largest share by 2026, owing to the presence of key players such as Genentech and Oxford Biomedical, who are investing largely for the improvement of the new technology which can be used in the growth of new testing techniques and advancement of the existing ones. North America leads the market because of the high cognizance among consumers and drug creators regarding the welfares of genetic testing such as reduced side effects and augmented reliability. On the other hand, Asia-Pacific market is anticipated to be the fastest-growing region for the global genetic testing market. The genetic testing market in APAC is expected to grow at a rapid pace driven by the growth of molecular biology applications and technological breakthroughs. Child health, cancer risk studies, and infectious disease testing are the most common forms of genetic testing in APAC.

The genetic testing market is segmented based on its types which are sub-divided into predictive and presymptomatic testing, diagnostic testing, newborn and prenatal testing & preimplantation genetic diagnosis. Predictive testing is a method of genetic analysis. It is also recognized as presymptomatic analysis. These types of analysis are used to identify gene alterations connected with conditions that emerge after birth. Diagnostic testing is performed in order to rule out or confirm the chromosomal or genetic abnormalities associated with a person. Newborn screening is done just after the baby is born in order to test the genetic disorders so that it can be treated in early life stage. Screening methods deal with developmental, genetic, and metabolic abnormalities in the fetus or newborn. Newborn screening involves analyzing for certain harmful or potentially fatal disorders that are not otherwise noticeable at birth. Screening methods include NIPT and MSS.

The major market players in the global genetic testing market are:

  • QIAGEN N.V.
  • OXFORD BIODYNAMICS LIMITED
  • LUMINEX CORPORATION
  • CEPHEID
  • ROCHE DIAGNOSTICS CORPORATION

Company Profiles covers analysis of important players.

Qiagen was incorporated in 1986 and is headquartered in KJ Venlo, the Netherlands. Qiagen achieved a healthy market position in the Sample Assay and Technologies market and is mainly focused on building a strong global position in the field of healthcare. The company markets over 500 core products that are distributed in various combinations. ROCHE diagnostics corporation provides solutions, instrument systems, tests, software, and services that support clinical decision making in a variety of indication fields, including virology, oncology, inflammatory, cardiovascular, and infectious diseases.

Key Findings of the Global Genetic testing market:

  • Asia Pacific is the fastest growing region
  • Diagnostic testing is leading the genetic testing market by type
  • In terms of application, cancer market holds the largest market share
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
    • ESTIMATION METHODOLOGY
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • ASIA PACIFIC IS THE FASTEST GROWING REGION
      • DIAGNOSTIC TESTING IS LEADING THE GENETIC TESTING MARKET BY TYPE
      • CANCER MARKET HOLDS THE LARGEST MARKET SHARE, BY APPLICATIONS
  1. MARKET DETERMINANTS
    • MARKET DRIVERS
      • DIAGNOSING GENETIC DISORDERS
      • RISE IN INCIDENCE OF GENETIC DISEASES
      • SIMPLE ACCESSIBLE PROCEDURE
      • RNA PIPELINE TESTS RISING
      • ADVANCES IN GENETIC TESTING FOR CANCER
      • AGING POPULATION ON THE RISE
    • MARKET RESTRAINTS
      • INACCURACIES IN RESULTS
      • REIMBURSEMENT ISSUES
      • PSYCHOLOGICAL IMPACT
      • LACK OF PRECISION IN TESTING
    • MARKET OPPORTUNITIES
      • GENETIC COUNSELLING
      • EXPANSION OF BREAST CANCER GENES TESTING MARKET
      • NEW AND IMPROVED TECHNOLOGY
    • MARKET CHALLENGES
      • HIGH COST OF MEDICATION AND TESTS
      • HIGH COST OF RAW MATERIAL
      • RISE IN GENETIC DISCRIMINATION
  1. MARKET SEGMENTATION
    • MARKET BY TYPES 2018-2026
      • PREDICTIVE AND PRESYMPTOMATIC TESTING
      • DIAGNOSTIC TESTING
      • NEWBORN AND PRENATAL TESTING
        • SCREENING METHODS
          • NIPT
          • MSS
        • DIAGNOSTIC TECHNIQUES
          • PCR
          • FISH
          • CGH
        • PREIMPLANTATION GENETIC DIAGNOSIS
    • MARKET BY APPLICATION 2018-2026
      • CANCER GENETIC TESTING
      • PRENATAL GENETIC TESTING
      • PHARMACOGENOMICS
      • PREDISPOSITION MARKET
  1. KEY ANALYTICS
    • PORTER’S FIVE FORCES ANALYSIS
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTES
      • BARGAINING POWER OF BUYERS
      • BARGAINING POWER OF SUPPLIERS
      • THREAT OF RIVALRY
    • KEY BUYING CRITERIA
      • COST
      • ACCURACY
      • AVAILABILITY
      • RELIABILITY
    • MARKET TRENDS
      • HEALTH INFORMATION IS RISING SIGNIFICANTLY
      • INCREASING DEMAND FOR PERSONALIZED MEDICINE
      • NEW PRODUCT LAUNCHES
      • TECHNOLOGY ADVANCEMENTS
  1. GEOGRAPHIC ANALYSIS
    • NORTH AMERICA
      • UNITED STATES (U.S.)
      • CANADA
    • EUROPE
      • UNITED KINGDOM
      • FRANCE
      • GERMANY
      • SPAIN
      • ITALY
      • REST OF EUROPE
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • KOREA
      • REST OF APAC
    • REST OF THE WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND NORTH AFRICA
      • REST OF AFRICA
  1. COMPANY PROFILING
    • CEPHEID
    • DAAN DIAGNOSTICS LTD.
    • GENENTECH, INC
    • GENOMICTREE, INC.
    • HTG MOLECULAR DIAGNOSTICS, INC.
    • ILLUMINA, INC
    • INTEGRAGEN S.A
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • LUMINEX CORPORATION
    • MOLECULARMD, CORP
    • NATERA, INC
    • OXFORD BIODYNAMICS LIMITED
    • PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
    • PERKINELMER, INC.
    • QIAGEN N.V.
    • ROCHE DIAGNOSTICS CORPORATION

 

LIST OF TABLES

TABLE 1        GLOBAL GENETIC TESTING MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE 2        COST OF SELECTED DRUGS IN CANCER THERAPY

TABLE 3        GLOBAL GENETIC TESTING MARKET BY TYPE 2018-2026 ($ MILLION)

TABLE 4        GLOBAL GENETIC TESTING MARKET IN PREDICTIVE AND PRESYMPTOMATIC TESTING BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE 5        GLOBAL GENETIC TESTING MARKET IN DIAGNOSTIC TESTING BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE 6        GLOBAL NEWBORN AND PRENATAL TESTING MARKET BY TECHNOLOGY 2018-2026 ($ MILLION)

TABLE 7        CORE DISORDERS ASSOCIATED WITH NEWBORN SCREENING

TABLE 8        GLOBAL GENETIC TESTING MARKET IN NEWBORN AND PRENATAL TESTING BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE 9        COMPARISON BETWEEN SCREENINGS VERSUS DIAGNOSTIC TESTING

TABLE 10      GLOBAL NEWBORN AND PRENATAL TESTING IN SCREENING METHOD 2018-2026 ($ MILLION)

TABLE 11      GLOBAL NEWBORN AND PRENATAL TESTING IN DIAGNOSTIC TECHNIQUES 2018-2026 ($ MILLION)

TABLE 12      GLOBAL GENETIC TESTING MARKET BY APPLICATION 2018-2026 ($ MILLION)

TABLE 13      GENETICALLY LINKED CANCER

TABLE 14      NORTH AMERICA GENETIC TESTING MARKET BY COUNTRY 2018-2026 ($ MILLION)

TABLE 15      INCIDENCE RATES OF LEADING CHRONIC DISORDERS IN EUROPE, 2015

TABLE 16      EUROPE GENETIC TESTING MARKET 2018-2026

TABLE 17      PERCENTAGE OF DEATHS OF ALL AGES (ALL AGES) IN UK, 2015

TABLE 18      ASIA PACIFIC GLOBAL GENETIC TESTING MARKET BY COUNTRIES 2018-2026 ($ MILLION)

TABLE 19      REST OF WORLD GENETIC TESTING MARKET 2018-2026 ($ MILLION)

 

LIST OF FIGURES

FIGURE 1      GLOBAL GENETIC TESTING MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)

FIGURE 2      SAMPLES TYPES IN GENETIC TESTING

FIGURE 3      GLOBAL GERIATRIC POPULATION (65+) 2015 & 2020 (MILLION)

FIGURE 4      PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050

FIGURE 5      LAB AUTOMATION TECHNOLOGY BENEFITS GENETIC DIAGNOSTIC INDUSTRIES

FIGURE 6      GLOBAL GENETIC TESTING MARKET BY TYPE 2018-2026 ($ MILLION)

FIGURE 7      GLOBAL GENETIC TESTING MARKET IN PREDICTIVE AND PRESYMPTOMATIC TESTING 2018-2026 ($ MILLION)

FIGURE 8      GLOBAL GENETIC TESTING MARKET IN DIAGNOSTIC TESTING 2018-2026 ($ MILLION)

FIGURE 9      GLOBAL NEWBORN AND PRENATAL TESTING MARKET 2018-2026 ($ MILLION)

FIGURE 10   NEWBORN SCREENING IN UNITED STATES

FIGURE 11   FACTORS FOR BIRTH DEFECTS

FIGURE 12   GLOBAL SCREENING METHODS IN NIPT 2018-2026 ($ MILLION)

FIGURE 13   GLOBAL SCREENING METHODS IN MSS 2018-2026 ($ MILLION)

FIGURE 14   GLOBAL DIAGNOSTIC TECHNIQUES IN PCR 2018-2026 ($ MILLION)

FIGURE 15   GLOBAL DIAGNOSTIC TECHNIQUES IN FISH 2018-2026 ($ MILLION)

FIGURE 16   GLOBAL DIAGNOSTIC TECHNIQUES IN CGH 2018-2026 ($ MILLION)

FIGURE 17   GLOBAL GENETIC TESTING MARKET IN PREIMPLANTATION GENETIC DIAGNOSIS  2018-2026 ($ MILLION)

FIGURE 18   GLOBAL GENETIC TESTING MARKET BY APPLICATION 2018-2026

FIGURE 19   GLOBAL GENETIC TESTING MARKET FOR CANCER GENETIC TESTING 2018-2026 ($ MILLION)

FIGURE 20   GLOBAL NEW CANCER CASES AND MORTALITY RATE IN MILLION (2015-2030)

FIGURE 21   GLOBAL GENETIC TESTING MARKET  IN PRENATAL 2018-2026 ($ MILLION)

FIGURE 22   GLOBAL GENETIC TESTING MARKET IN PHARMACOGENOMICS 2018-2026 ($ MILLION)

FIGURE 23   GLOBAL GENETIC TESTING MARKET IN PREDISPOSITION 2018-2026 ($ MILLION)

FIGURE 24   NUMBER OF NEW CASES FOUND IN THE NORTH AMERICAN COUNTRIES 2016

FIGURE 25   NORTH AMERICA RESPIRATORY CARE DEVICE MARKET SHARE BY COUNTRIES

FIGURE 26   CANCER CASES IN THE U.S. 2016

FIGURE 27   HEALTHCARE EXPENDITURE IN THE U.S. 2014-2025 (% OF GDP)

FIGURE 28   GLOBAL UNITED STATES GENETIC TESTING MARKET 2018-2026 ($ MILLION)

FIGURE 29   TYPES OF NEW CASES OF CANCER IN CANADA 2015

FIGURE 30   HEALTHCARE FINANCING IN CANADA 2015 (%)

FIGURE 31   CANADA GENETIC TESTING MARKET 2018-2026 ($ MILLION)

FIGURE 32   UNITED KINGDOM GENETIC TESTING MARKET 2018-2026 ($ MILLION)

FIGURE 33   PERCENTAGE OF DEATHS IN FRANCE, 2015

FIGURE 34   FRANCE GENETIC TESTING MARKET 2018-2026 ($ MILLION)

FIGURE 35   PERCENTAGE OF ALL DEATHS (ALL AGES) IN GERMANY, 2015

FIGURE 36   GERMANY GENETIC TESTING MARKET 2018-2026 ($ MILLION)

FIGURE 37   PERCENTAGE OF DEATHS IN SPAIN, 2015

FIGURE 38   SPAIN GENETIC TESTING MARKET 2018-2026 ($ MILLION)

FIGURE 39   ITALY GENETIC TESTING MARKET 2018-2026 ($ MILLION)

FIGURE 40   REST OF EUROPE GENETIC TESTING MARKET 2018-2026 ($ MILLION)

FIGURE 41   PERCENTAGE OF AGING POPULATION IN ASIA 2010 AND 2050

FIGURE 42   CANCER INCIDENCE RATE IN ASIAN COUNTRIES BY GENDER 2015

FIGURE 43   INDIA GENETIC TESTING MARKET 2018-2026($ MILLION)

FIGURE 44   CHINA GENETIC TESTING MARKET 2018-2026 ($MILLION)

FIGURE 45   JAPAN GENETIC TESTING MARKET 2018-2026 ($ MILLION)

FIGURE 46   BIOTECHNOLOGY COMPANIES IN KOREA 2015

FIGURE 47   KOREA GENETIC TESTING MARKET 2018-2026($ MILLION)

FIGURE 48   REST OF APAC GENETIC TESTING MARKET 2018-2026($ MILLION)

FIGURE 49   REST OF WORLD GENETIC TESTING MARKET 2018-2026 ($ MILLION)

FIGURE 50   CHRONIC DISEASE DEATH RATES (PER 100,000), 2015

FIGURE 51   TYPE OF DISEASES IN LATIN AMERICA 2015 (%)

FIGURE 52   LATIN AMERICA GENETIC TESTING MARKET 2018-2026 ($ MILLION)

FIGURE 53   MENA GENETIC TESTING MARKET 2018-2026 ($ MILLION)

FIGURE 54   REST OF AFRICA GENETIC TESTING MARKET 2018-2026 ($ MILLION)

  1. MARKET SEGMENTATION
    • MARKET BY TYPES 2018-2026
      • PREDICTIVE AND PRESYMPTOMATIC TESTING
      • DIAGNOSTIC TESTING
      • NEWBORN AND PRENATAL TESTING
        • SCREENING METHODS
          • NIPT
          • MSS
        • DIAGNOSTIC TECHNIQUES
          • PCR
          • FISH
          • CGH
        • PREIMPLANTATION GENETIC DIAGNOSIS
    • MARKET BY APPLICATION 2018-2026
      • CANCER GENETIC TESTING
      • PRENATAL GENETIC TESTING
      • PHARMACOGENOMICS
      • PREDISPOSITION MARKET
  1. GEOGRAPHIC ANALYSIS
    • NORTH AMERICA
      • UNITED STATES (U.S.)
      • CANADA
    • EUROPE
      • UNITED KINGDOM
      • FRANCE
      • GERMANY
      • SPAIN
      • ITALY
      • REST OF EUROPE
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • KOREA
      • REST OF APAC
    • REST OF THE WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND NORTH AFRICA
      • REST OF AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now